Innocan Pharma Corporation

Recent News

Innocan Reports Q3 2020 Financial Results

Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today its financial and business results for the three and nine months period ended September 30, 2020 (the "Financial Statements") and provide highlights and comments on these results. This news release should be read in conjunction with the Financial Statements and corresponding Management's Discussion and Analysis...

2020-12-02 3:00 AM EST

Innocan Moves to an Advanced Efficacy Trial on Animals of Its Liposome-CBD Injection, Following Encouraging Results on the First Stage

Israel and Calgary, Alberta--(Newsfile Corp. - November 16, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan's CBD loaded liposome platform technology ("LPT") in relevant diseases. These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into...

2020-11-16 3:00 AM EST

Innocan Enters Into Distribution Agreement to Sell its CBD Derma Cosmetic Products in Germany

Israel and Calgary, Alberta--(Newsfile Corp. - November 11, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel") has entered into a distribution agreement dated 4, 2020 (the "Agreement") with iAmHealth Distribution UG ("iAmHealth"), a CBD products provider in Germany to sell the Company's SHIR Beauty and Relief & Go product lines in Germany. Under the terms of the...

2020-11-11 4:00 PM EST

Innocan Pharma's Relief & Go CBD Spray Successfully Passes Safety Assessments and is Approved for Marketing in the European Union

Israel and Calgary, Alberta--(Newsfile Corp. - October 27, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report ("CPSR") for product marketing in the European Union.

2020-10-27 5:00 PM EDT

Innocan Pharma Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells

Israel and Calgary, Alberta--(Newsfile Corp. - October 23, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce the recent publication of two scientific articles supporting Innocan's approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19. The first paper entitled, "Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients" published in the...

2020-10-23 3:00 AM EDT

Innocan Pharma's Clinical Study in the US Indicates that More than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief &Go OTC Pain Relief Spray

Israel and Calgary, Alberta--(Newsfile Corp. - October 19, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today a Clinical Study, conducted by Dr. Josef Geldwert and the Center for Podiatric Care & Sports Medicine in New York. The study indicates that more than 90 % of participants experienced reduction in pain after using Innocan's Relief & Go OTC Pain Relief Spray. The clinical study was conducted on 18 participants: 10...

2020-10-19 4:00 PM EDT

Innocan Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

Israel and Calgary, Alberta--(Newsfile Corp. - October 9, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today that an animal study on mice, demonstrated a prolonged release of Cannabidiol ("CBD") into the blood for at least three weeks after one administration. This study was conducted by The Hebrew University of Jerusalem, Israel based on Innocan's licensed CBD loaded liposome platform technology ("LPT") for injectable CBD. The...

2020-10-09 4:00 PM EDT

Innocan Pharma to Provide a Corporate Update via Livestream Video

Israel and Calgary, Alberta--(Newsfile Corp. - October 8, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST. The update will include a corporate presentation by Innocan's CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific...

2020-10-08 4:00 PM EDT

Innocan Phrama Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration

Israel and Calgary, Alberta--(Newsfile Corp. - September 15, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today, that it has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol ("CBD") (the "Serum") on skin hydration.

2020-09-15 4:00 PM EDT

Innocan Pharma to Amend Warrants Held by Tamar Technologies Ltd.

Toronto, Ontario--(Newsfile Corp. - September 14, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), announces that its board of directors has agreed to amend the terms of certain common share purchase warrants (the "Warrants") held by Tamar Innovest Ltd. (formerly, Solsken Ltd.) ("Tamar").The Warrants were issued by the Company on April 15, 2019 and consist of: (a) 13,981,916 Warrants at an exercise price of US $0.1252 expiring April 15, 2021 pursuant to...

2020-09-14 4:00 PM EDT

Innocan Pharma Announces Publication of Enterprise Report by Mackie Research

Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that Mackie Research Capital Corporation's institutional sales group has issued an updated Enterprise report on the Company. The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into...

2020-09-03 3:08 AM EDT

Innocan to Distribute Its CBD Line of Products in Italy and Switzerland

Israel and Calgary, Alberta--(Newsfile Corp. - August 20, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel") has entered into a distribution agreement (the "Agreement") with a Swiss CBD provider called Cloud 9 Switzerland LLC ("Cloud 9") to sell the Company's SHIRTM Beauty and Relief & Go product lines in Italy and Switzerland.Under the terms of the Agreement,...

2020-08-20 4:00 PM EDT

Innocan Engages Endless Sky to Manufacture and Distribute Innocan's CBD Cosmetic Products in Canada

Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel") has entered into a manufacturing and distribution agreement (the "Agreement") with Endless Sky Incorporated ("ESI"), a Canadian large scale Cannabis extractor based in Calgary, Alberta.Under the Agreement, ESI will serve as the exclusive distributor of...

2020-08-11 4:00 PM EDT

Innocan's SHIR (TM) Beauty & Science CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union

Israel and Calgary, Alberta--(Newsfile Corp. - August 6, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic Product Safety Report for marketing in the European Union. SHIR™ skincare products combine the benefits of CBD with the most effective...

2020-08-06 4:31 PM EDT

Innocan's Over-The-Counter Pain Relief Spray Receives FDA's Technical Validation for Marketing in the USA

Israel and Calgary, Alberta--(Newsfile Corp. - July 13, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it has received notice from the FDA that Innocan's over-the-counter Relief & Go Pain Relief spray product has successfully received technical validation and approval to commence marketing in the USA. Innocan's pain relief formulation contains a combination of Magnesium oil, Methyl salicylate, Menthol and CBD. The Relief &...

2020-07-13 2:00 AM EDT

InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments

Israel and Calgary, Alberta--(Newsfile Corp. - July 9, 2020) - InnoCan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes.Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas, pharmaceutical development services and manufacturing services. Recipharm offers seamless...

2020-07-09 3:00 AM EDT

Innocan Pharma's Corporate Update

Calgary, Alberta--(Newsfile Corp. - July 2, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan") announced today that Mr. Bill Macdonald has resigned as a member of the Company's board of directors effective June 29, 2020. The Company wishes to thank Mr. Macdonald for all his efforts and supporting the Company since the IPO in September 2019. The Company also announced today that it reached an agreement with a former service provider to settle certain debt...

2020-07-02 9:12 AM EDT

InnoCan Pharma Announces the Successful Completion of an Independent Clinical Study Demonstrating Safety and Skin Tolerance of Its CBD Derma Cosmetic Line

Israel and Calgary, Alberta--(Newsfile Corp. - June 26, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce the results from the first Dermal clinical study of Relief & Go ™ and Shir ™ product lines. The double blinded randomized controlled study assessed the tolerance degree of the Company's CBD Topicals products and demonstrated the products to be non-irritating to the skin. InnoCan's contract manufacturer for these products,...

2020-06-26 3:00 AM EDT

Innocan Pharma Announces Mackie Research's Institutional Sales Group Issues Enterprise Publication on the Company

Israel and Calgary, Alberta--(Newsfile Corp. - June 22, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that Mackie Research Capital Corporation's institutional sales group has issued an Enterprise publication on the Company. The Enterprise publication provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into...

2020-06-22 3:20 AM EDT

InnoCan Signs Letter of Intent with Tamar to Distribute and Supply CBD "API" for use in InnoCan's Research Projects

Israel and Calgary, Alberta--(Newsfile Corp. - June 17, 2020) - InnoCan Pharma Corporation (CSE: INNO) (FSE: IP4) ("InnoCan" or the "Company") announced that it has signed a non-binding Letter of Intent with its major shareholder Tamar Innovest Ltd (formerly Solsken Ltd) ("Tamar"), a wholly owned subsidiary of Tamar Technologies Limited ("Tamar Tech") whereby, subject to the entering into of a formal agreement between the parties, Tamar will distributenaturally sourced CBD, certified as an...

2020-06-17 3:00 AM EDT

Ready to Announce with Confidence?

Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us